目的 探讨杏贝止咳颗粒辅助治疗老年慢性阻塞性肺疾病（COPD）稳定期患者的临床疗效。方法 选取2019年12月—2021年12月南京市高淳人民医院呼吸科门诊就诊的COPD稳定期患者88例，按照随机数字表法分为对照组和试验组，每组各44例。对照组患者使用常规药物［布地奈德福莫特罗吸入粉雾剂（II）］联合健康教育治疗；试验组在对照组的基础上加用杏贝止咳颗粒治疗，两组均治疗6个月。分别于治疗前及治疗24周后测定两组患者肺功能指标［第1秒用力呼气容积（FEV1）、第1秒用力呼气容积占预计值百分比（FEV1%）、用力肺活量（FVC）］，分别于治疗前后对两组患者进行焦虑自评量表（SAS）和抑郁自评量表（SDS）评分以及日常生活质量（ADL）和COPD患者生活质量（CAT）评分。观察两组患者治疗期间不良反应发生情况。结果 两组研究对象的一般人口学资料（年龄、性别、婚姻状况、文化程度、月平均收入等）比较，差异均无统计学意义（P＞0.05）；两组研究对象的疾病相关资料（病程、合并疾病、吸氧、氧疗、呼吸困难严重程度、注射疫苗等）比较，差异均无统计学意义（P＞0.05）。治疗后两组患者SAS和SDS评分均较本组治疗前显著降低（P＜0.05），且治疗后试验组SAS和SDS评分显著低于对照组（P＜0.05）。治疗后两组FEV1均较本组治疗前有显著升高（P＜0.05），FEV1%和FEV1/FVC均显著升高（P＜0.05）；且治疗后，与对照组比较试验组FEV1、FEV1%和FEV1/FVC均显著升高（P＜0.05）；治疗后两组ADL评分均较本组治疗前显著升高（P＜0.05），CAT评分均较本组治疗前显著降低（P＜0.05）；且治疗后，与对照组比较试验组ADL评分显著升高（P＜0.05），CAT评分显著降低（P＜0.05）。两组治疗期间均未出现明显不良反应。结论 杏贝止咳颗粒辅助治疗COPD稳定期患者能有效缓解患者焦虑抑郁状态、改善肺功能，提高患者的生存质量，值得临床推广。

Objective To explore the clinical efficacy of Xingbei Zhike Granule in the adjuvant treatment of elderly patients with chronic obstructive pulmonary disease (COPD) at stable stage.Methods A total of 88 patients with stable COPD from the respiratory department of Nanjing Gaochun People's Hospital from December 2019 to December 2021 were randomly selected, and divided into control group and experimental group according to random number method, with 44 patients in each group. Patients in the control group were treated with conventional drugs [Budesonide Formoterol Inhalation Powder Spray (II)] combined with health education. Patients in the experimental group were treated with Xingbei Zhike Granule on the basis of the control group, and both groups were treated for six months. The pulmonary function indexes (FEV1, FEV1%, FEV1/FVC) of the patients in the two groups were measured before and after treatment. The patients in the two groups were scored with the Self Rating Anxiety Scale (SAS) and the Self Rating Depression Scale (SDS) before and after treatment, as well as the quality of daily life (ADL) and the quality of life (CAT) of the patients with COPD. The adverse reactions of the two groups were observed during treatment.Results There was no significant difference in general demographic data (age, sex, marital status, education level, average monthly income, etc.) between the two groups (P > 0.05). There was no significant difference between the two groups in disease related data (course of disease, concomitant diseases, oxygen inhalation, oxygen therapy, severity of dyspnea, vaccine injection, etc.) (P > 0.05). After treatment, the SAS and SDS scores of the two groups were significantly lower than those before treatment (P <0.05), and the SAS and SDS scores of the experimental group were significantly lower than those of the control group (P <0.05). After treatment, FEV1 in both groups was significantly higher than that before treatment (P <0.05), FEV1% and FEV1/FVC increased significantly (P <0.05). After treatment, FEV1, FEV1% and FEV1/FVC in the experimental group were significantly higher than those in the control group (P <0.05). After treatment, ADL scores in both groups were significantly higher than those before treatment (P <0.05), and CAT scores were significantly lower than those before treatment (P <0.05). After treatment, compared with the control group, the ADL score in the experimental group was significantly higher (P <0.05), while the CAT score was significantly lower (P <0.05). There was no obvious adverse reaction in both groups during treatment.Conclusion Xingbei Zhike Granule can effectively relieve anxiety and depression, improve lung function, and improve the quality of life of patients with stable COPD, which is worthy of clinical promotion.

R974

南京市中医药青年人才培养计划项目(ZYQ20065);江苏省老年健康科研项目(LSD2022005)